Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate: Number of participants with any adverse event (primary tolerability outcome)
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate Primary: adverse events ‐ at least 1 adverse event · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional… Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty). Interventions for hand eczema (2019) · Cochrane Headline outcomes only | RR 1.22 [0.8, 1.86] | 1 study · 55 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for hand eczema 2019 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.